Pfizer, Bristol-Myers’s Eliquis Fails to Win FDA Approval

Pfizer Inc. and Bristol-Myers Squibb Co. failed to gain approval of their top experimental drug, the blood thinner Eliquis, from U.S. regulators who said they needed more data on the treatment.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.